

PTO/SB/63 (10-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

nder the Paperwork Haduction at \$ 995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Docket Number (Optional)

## TERMINAL DISCLAIMER TO ACCOMPANY PETITION In re Application of: Christine L. Brakel et al. Name: Application Number: 08/479,999 June 28, 1994 For: Modified Nucleotide Compounds of \_\_\_\_\_percent interest in the above-identified application The owner\*, hereby disclaims a terminal part of the term of any patent granted the above-identified application equivalent to: (1) if the above-identified application is a design application, the period of abandonment of the aboveidentified application, and (2) if the above-identified application is a utility or plant application, the lesser of: (a) the period of abandonment of the application; or (b) the period extending beyond twenty years from the date on which the above-identified application was filed in the United States or, if the application contains a specific reference to an earlier filed application(s) under 35 U.S.C. 120, 121, or 365(c), from the date on which the earliest such application was filed. This disclaimer also applies to any patent granted on a utility or plant application filed before June 8, 1995, or a design application, that contains a specific reference under 35 U.S.C. 120, 121, or 365(c) to the above-identified application. This disclaimer is binding upon the grantee, and its successors or assigns. Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. The undersigned is an attorney or agent of record. 12/26/01 Date Ronald C. Fedus Typed or printed name Req. No. 32,567 Terminal disclaimer fee under 37 CFR 1.20(d) included. The Patent and Trademark Office is hereby authorized to charge Deposit Account No. 05-1135 for WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. \*\* the Terminal Disclaimer fee under 37 C.F.R. 1.20(d) and for any other required fees. \* Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.